Ontology highlight
ABSTRACT:
SUBMITTER: Gross-Goupil M
PROVIDER: S-EPMC3825605 | biostudies-other | 2013 Oct
REPOSITORIES: biostudies-other
Clinical Medicine Insights. Oncology 20131029
Over the last seven years, seven targeted agents have been approved in the treatment of advanced or metastatic renal cell cancer, changing the therapeutic approach and prognosis of the disease dramatically. The latest agent with demonstrated efficacy is axitinib (Inlyta(®)). This new generation of tyrosine kinase agent differs from previously existing agents by its greater activity potency of inhibition of vascular endothelial growth factor-receptor (VEGFR1-3). This efficacy has been tested in p ...[more]